Macrogenics (MGNX) Tops Q2 EPS, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- S&P 500, Nasdaq drop as tech megacap declines outweigh upbeat Micron forecast
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
August 9, 2023 4:01 PM EDTAdvancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofis announcement of positive top-line data from TZIELD® (teplizumab-mzwv) type 1 diabetes study Conference call scheduled for today at4:30 p.m. ET
 ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:... More
